Related Experiment Video
Updated: Jul 20, 2026

04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
[High flow priapism. Case report].
Anna Bujons1, X Pascual, J Martí
1Servicio de Urología Fundación Puigvert, Barcelona, España. abujons@gmail.com
Archivos Espanoles De Urologia
|August 29, 2006
Summary
Embolization of the internal pudendal artery effectively resolved high-flow priapism caused by an arteriovenous fistula. This case study highlights a successful treatment for a persistent priapism condition.
Area of Science:
- Urology
- Interventional Radiology
- Vascular Surgery
Background:
- Priapism, a prolonged erection, can lead to erectile dysfunction and requires prompt diagnosis and management.
- High-flow priapism, often secondary to perineal trauma and arteriovenous fistula (AVF) formation, presents unique diagnostic and therapeutic challenges.
- Literature review indicates varied etiologies and presentations of priapism, necessitating a comprehensive approach to differential diagnosis.
Observation:
- A patient presented with a four-year history of recurrent priapism.
- Clinical and radiological assessments were performed to determine the underlying cause.
- An arteriovenous fistula involving the internal pudendal artery was identified as the etiology.
Findings:
- The patient underwent successful embolization of the internal pudendal artery.
- Post-embolization, the patient experienced complete resolution of priapism.
- Radiological imaging confirmed the closure of the arteriovenous fistula.
Implications:
- Percutaneous embolization of the internal pudendal artery is a highly effective treatment for high-flow priapism secondary to AVF.
- This minimally invasive approach offers a viable solution for refractory priapism cases, preserving erectile function.
- The findings support interventional radiology as a key modality in managing complex vascular abnormalities causing priapism.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

